|
The Journal of Lipid Research, Vol. 39, 457-462, February 1998
Copyright © 1998 by Lipid Research, Inc.
Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet
Joan Carles Escolà-Gila,b,
Àfrica Marzal-Casacubertaa,b,c,
Josep Julve-Gila,b,
Brian Y. Ishidad,
Jordi Ordóñez-Llanosa,c,
Lawrence Chane,
Francesc González-Sastrea,c, and
Francisco Blanco-Vacaa,b
a Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
b Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
c Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
d Department of Medicine, University of California-San Francisco, San Francisco, CA
e Departments of Cell Biology and Medicine, Baylor College of Medicine, Houston, TX
Correspondence to:
Francisco Blanco-Vaca.
We report on the effect of human apolipoprotein (apo) A-II transgene expression on atherosclerosis susceptibility in two transgenic lines (25.3 and 11.1) whose plasma human apoA-II concentrations (~23 and 96 mg/dl, respectively) span the normal range in humans. After 9 months of an atherogenic diet, 25.3 and 11.1 transgenic mice developed aortic atherosclerotic lesions that were ~1.7- and 7-fold, respectively, more extensive than those of nontransgenic control mice. However, there was no difference in the area of atherosclerosis of transgenic and control mice when fed a regular chow diet. This contrasts with the findings in murine apoA-II transgenic mice and provides evidence of a species-specific characteristic that could be of relevance with respect to the high fat intake diets common in most industrialized countries. A possible mechanism of the pro-atherogenic action of human apoA-II could be the inhibition of reverse cholesterol transport and, in support of this, we observed an impairment of apoA-I-HDL particle interconversion in the plasma of 11.1 transgenic mice caused, at least in part, by a marked decrease in the endogenous lecithin:cholesterol acyltransferase activity.Escolà-Gil, J. C., À. Marzal-Casacuberta, J. Julve-Gil, B. Y. Ishida, J. Ordóñez-Llanos, L. Chan, F. González-Sastre, and F. Blanco-Vaca. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J. Lipid Res. 1998. 39: 457462.
Supplementary key words:
high density lipoproteins, atherosclerosis, apolipoprotein A-I, lecithin:cholesterol acyltransferase

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Koike, S. Kitajima, Y. Yu, Y. Li, K. Nishijima, E. Liu, H. Sun, A. B. Waqar, N. Shibata, T. Inoue, et al.
Expression of Human ApoAII in Transgenic Rabbits Leads to Dyslipidemia: A New Model for Combined Hyperlipidemia
Arterioscler Thromb Vasc Biol,
December 1, 2009;
29(12):
2047 - 2053.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Corella, G. Peloso, D. K. Arnett, S. Demissie, L. A. Cupples, K. Tucker, C.-Q. Lai, L. D. Parnell, O. Coltell, Y.-C. Lee, et al.
APOA2, Dietary Fat, and Body Mass Index: Replication of a Gene-Diet Interaction in 3 Independent Populations
Arch Intern Med,
November 9, 2009;
169(20):
1897 - 1906.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. W. Castellani, C. N. Nguyen, S. Charugundla, M. M. Weinstein, C. X. Doan, W. S. Blaner, N. Wongsiriroj, and A. J. Lusis
Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance
J. Biol. Chem.,
April 25, 2008;
283(17):
11633 - 11644.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Birjmohun, G. M. Dallinga-Thie, J. A. Kuivenhoven, E. S.G. Stroes, J. D. Otvos, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, and S. M. Boekholdt
Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease
Circulation,
October 30, 2007;
116(18):
2029 - 2035.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Corella, D. K. Arnett, M. Y. Tsai, E. K. Kabagambe, J. M. Peacock, J. E. Hixson, R. J. Straka, M. Province, C.-Q. Lai, L. D. Parnell, et al.
The -256T>C Polymorphism in the Apolipoprotein A-II Gene Promoter Is Associated with Body Mass Index and Food Intake in the Genetics of Lipid Lowering Drugs and Diet Network Study
Clin. Chem.,
June 1, 2007;
53(6):
1144 - 1152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. G. D. Silva, L. A. Schneeweis, S. C. Krishnan, X. Zhang, P. H. Axelsen, and W. S. Davidson
The Structure of Apolipoprotein A-II in Discoidal High Density Lipoproteins
J. Biol. Chem.,
March 30, 2007;
282(13):
9713 - 9721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Nissen, S. J. Nicholls, K. Wolski, D. C. Howey, E. McErlean, M.-D. Wang, E. V. Gomez, and J. M. Russo
Effects of a Potent and Selective PPAR-{alpha} Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia: Two Randomized Controlled Trials
JAMA,
March 28, 2007;
297(12):
1362 - 1373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Rotllan, V. Ribas, L. Calpe-Berdiel, J. M. Martin-Campos, F. Blanco-Vaca, and J. C. Escola-Gil
Overexpression of Human Apolipoprotein A-II in Transgenic Mice Does Not Impair Macrophage-Specific Reverse Cholesterol Transport In Vivo
Arterioscler Thromb Vasc Biol,
September 1, 2005;
25(9):
e128 - e132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. W. Castellani, P. Gargalovic, M. Febbraio, S. Charugundla, M.-L. Jien, and A. J. Lusis
Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II
J. Lipid Res.,
December 1, 2004;
45(12):
2377 - 2387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Ribas, J. L. Sanchez-Quesada, R. Anton, M. Camacho, J. Julve, J. C. Escola-Gil, L. Vila, J. Ordonez-Llanos, and F. Blanco-Vaca
Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties: A New Mechanism Linking HDL Protein Composition and Antiatherogenic Potential
Circ. Res.,
October 15, 2004;
95(8):
789 - 797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. de Beer, L. W. Castellani, L. Cai, A. J. Stromberg, F. C. de Beer, and D. R. van der Westhuyzen
ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36
J. Lipid Res.,
April 1, 2004;
45(4):
706 - 715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Sauvaget, V. Chauffeton, S. Dugue-Pujol, A.-D. Kalopissis, I. Guillet-Deniau, F. Foufelle, J. Chambaz, A. Leturque, P. Cardot, and A. Ribeiro
In Vitro Transcriptional Induction of the Human Apolipoprotein A-II Gene by Glucose
Diabetes,
March 1, 2004;
53(3):
672 - 678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Allayee, L. W. Castellani, R. M. Cantor, T. W.A. de Bruin, and A. J. Lusis
Biochemical and Genetic Association of Plasma Apolipoprotein A-II Levels With Familial Combined Hyperlipidemia
Circ. Res.,
June 13, 2003;
92(11):
1262 - 1267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Julve, J. C. Escola-Gil, V. Ribas, F. Gonzalez-Sastre, J. Ordonez-Llanos, J. L. Sanchez-Quesada, and F. Blanco-Vaca
Mechanisms of HDL deficiency in mice overexpressing human apoA-II
J. Lipid Res.,
October 1, 2002;
43(10):
1734 - 1742.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Boisfer, D. Stengel, D. Pastier, P. M. Laplaud, N. Dousset, E. Ninio, and A.-D. Kalopissis
Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II
J. Lipid Res.,
May 1, 2002;
43(5):
732 - 741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Fournier, A. Cogny, V. Atger, D. Pastier, D. Goudouneche, A. Nicoletti, N. Moatti, J. Chambaz, J.-L. Paul, and A.-D. Kalopissis
Opposite Effects of Plasma From Human Apolipoprotein A-II Transgenic Mice on Cholesterol Efflux From J774 Macrophages and Fu5AH Hepatoma Cells
Arterioscler Thromb Vasc Biol,
April 1, 2002;
22(4):
638 - 643.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. W. Castellani and A. J. Lusis
ApoA-II Versus ApoA-I: Two for One Is Not Always a Good Deal
Arterioscler Thromb Vasc Biol,
December 1, 2001;
21(12):
1870 - 1872.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Blanco-Vaca, J. C. Escola-Gil, J. M. Martin-Campos, and J. Julve
Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein
J. Lipid Res.,
November 1, 2001;
42(11):
1727 - 1739.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Hedrick, L. W. Castellani, H. Wong, and A. J. Lusis
In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions
J. Lipid Res.,
April 1, 2001;
42(4):
563 - 570.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. C. Escolà-Gil, J. Julve, A. Marzal-Casacuberta, J. Ordóñez-Llanos, F. González-Sastre, and F. Blanco-Vaca
ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance
J. Lipid Res.,
February 1, 2001;
42(2):
241 - 248.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. von Eckardstein, J.-R. Nofer, and G. Assmann
High Density Lipoproteins and Arteriosclerosis : Role of Cholesterol Efflux and Reverse Cholesterol Transport
Arterioscler Thromb Vasc Biol,
January 1, 2001;
21(1):
13 - 27.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tailleux, M. Bouly, G. Luc, G. Castro, J.-M. Caillaud, N. Hennuyer, P. Poulain, J.-C. Fruchart, N. Duverger, and C. Fievet
Decreased Susceptibility to Diet-Induced Atherosclerosis in Human Apolipoprotein A-II Transgenic Mice
Arterioscler Thromb Vasc Biol,
November 1, 2000;
20(11):
2453 - 2458.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Escolà-Gil, J. Julve, A. Marzal-Casacuberta, J. Ordóñez-Llanos, F. González-Sastre, and F. Blanco-Vaca
Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia
J. Lipid Res.,
August 1, 2000;
41(8):
1328 - 1338.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. C. Escola-Gil, O. Jorba, J. Julve-Gil, F. Gonzalez-Sastre, J. Ordonez-Llanos, and F. Blanco-Vaca
Pitfalls of Direct HDL-Cholesterol Measurements in Mouse Models of Hyperlipidemia and Atherosclerosis
Clin. Chem.,
September 1, 1999;
45(9):
1567 - 1569.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Boisfer, G. Lambert, V. Atger, N. Q. Tran, D. Pastier, C. Benetollo, J.-F. Trottier, I. Beaucamps, M. Antonucci, M. Laplaud, et al.
Overexpression of Human Apolipoprotein A-II in Mice Induces Hypertriglyceridemia Due to Defective Very Low Density Lipoprotein Hydrolysis
J. Biol. Chem.,
April 23, 1999;
274(17):
11564 - 11572.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Fournier, A. Cogny, V. Atger, D. Pastier, D. Goudouneche, A. Nicoletti, N. Moatti, J. Chambaz, J.-L. Paul, and A.-D. Kalopissis
Opposite Effects of Plasma From Human Apolipoprotein A-II Transgenic Mice on Cholesterol Efflux From J774 Macrophages and Fu5AH Hepatoma Cells
Arterioscler Thromb Vasc Biol,
April 1, 2002;
22(4):
638 - 643.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|